title: Translational strategies for development of monoclonal antibodies from discovery to the clinic.
abstract: Successful strategies for the development of monoclonal antibodies require integration of knowledge with respect to target antigen properties, antibody design criteria such as affinity, isotype selection, Fc domain engineering, PK/PD properties and antibody cross-reactivity across species from the early stages of antibody development. Biophysical measurements are one of the critical components necessary for the design of effective translational strategies for lead selection and evaluation of relevant animal species for preclinical safety and efficacy studies. Incorporation of effective translational strategies from the early stages of the antibody development process is a necessity; when considered it not only reduces development time and cost, but also fosters implementation of rational decision-making throughout all phases of antibody development.
authors.affiliation: MedImmune, Hayward, CA 94545, USA. tabrizifardm@medimmune.com
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Tabrizi
authors.forename: Gadi Gazit
authors.initials: GG
authors.lastname: Bornstein
authors.forename: Scott L
authors.initials: SL
authors.lastname: Klakamp
authors.forename: Andrew
authors.initials: A
authors.lastname: Drake
authors.forename: Richard
authors.initials: R
authors.lastname: Knight
authors.forename: Lorin
authors.initials: L
authors.lastname: Roskos
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology*; D015415:Biomarkers; D002986:Clinical Trials as Topic; D003657:Decision Making; D016503:Drug Delivery Systems; D015195:Drug Design; D055808:Drug Discovery / Q000191:economics / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers